Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juha Taavela

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The American Journal of Gastroenterology|June 5, 2013
CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac diseaseBelén Morón, Anil K Verma, Prasenjit Das, et al.
The American Journal of Gastroenterology|January 6, 2016
A Prospective Study on the Usefulness of Duodenal Bulb Biopsies in Celiac Disease Diagnosis in Children: Urging CautionJuha Taavela, Alina Popp, Ilma Rita Korponay-Szabo, et al.
The Lancet. Gastroenterology & Hepatology|March 10, 2023
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 studyJason A Tye-Din, A James M Daveson, Gautam Goel, et al.
The Lancet. Gastroenterology & Hepatology|September 9, 2019
Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled studyMarja-Leena Lähdeaho, Mika Scheinin, Pekka Vuotikka, et al.
Nature Immunology|June 24, 2024
Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac diseaseValeriia Dotsenko, Bernhard Tewes, Martin Hils, et al.
Food & Function|January 14, 2022
Healthy and pro-inflammatory gut ecology plays a crucial role in the digestion and tolerance of a novel Gluten Friendly™ bread in celiac subjects: a randomized, double blind, placebo control <i>in vivo</i> studyAngelo Andriulli, Antonio Bevilacqua, Orazio Palmieri, et al.
Gut|February 15, 2018
Outcome measures in coeliac disease trials: the Tampere recommendationsJonas F Ludvigsson, Carolina Ciacci, Peter Hr Green, et al.
The New England Journal of Medicine|June 30, 2021
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac DiseaseDetlef Schuppan, Markku Mäki, Knut E A Lundin, et al.
The Lancet. Gastroenterology & Hepatology|May 17, 2017
Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studiesGautam Goel, Tim King, A James Daveson, et al.
Nutrients|June 24, 2022
Gluten Induces Subtle Histological Changes in Duodenal Mucosa of Patients with Non-Coeliac Gluten Sensitivity: A Multicentre StudyKamran Rostami, Arzu Ensari, Michael N Marsh, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The American Journal of Gastroenterology|June 5, 2013
CYP3A4-catalyzed simvastatin metabolism as a non-invasive marker of small intestinal health in celiac diseaseBelén Morón, Anil K Verma, Prasenjit Das, et al.
The American Journal of Gastroenterology|January 6, 2016
A Prospective Study on the Usefulness of Duodenal Bulb Biopsies in Celiac Disease Diagnosis in Children: Urging CautionJuha Taavela, Alina Popp, Ilma Rita Korponay-Szabo, et al.
The Lancet. Gastroenterology & Hepatology|March 10, 2023
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 studyJason A Tye-Din, A James M Daveson, Gautam Goel, et al.
The Lancet. Gastroenterology & Hepatology|September 9, 2019
Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled studyMarja-Leena Lähdeaho, Mika Scheinin, Pekka Vuotikka, et al.
Nature Immunology|June 24, 2024
Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac diseaseValeriia Dotsenko, Bernhard Tewes, Martin Hils, et al.
Food & Function|January 14, 2022
Healthy and pro-inflammatory gut ecology plays a crucial role in the digestion and tolerance of a novel Gluten Friendly™ bread in celiac subjects: a randomized, double blind, placebo control <i>in vivo</i> studyAngelo Andriulli, Antonio Bevilacqua, Orazio Palmieri, et al.
Gut|February 15, 2018
Outcome measures in coeliac disease trials: the Tampere recommendationsJonas F Ludvigsson, Carolina Ciacci, Peter Hr Green, et al.
The New England Journal of Medicine|June 30, 2021
A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac DiseaseDetlef Schuppan, Markku Mäki, Knut E A Lundin, et al.
The Lancet. Gastroenterology & Hepatology|May 17, 2017
Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studiesGautam Goel, Tim King, A James Daveson, et al.
Nutrients|June 24, 2022
Gluten Induces Subtle Histological Changes in Duodenal Mucosa of Patients with Non-Coeliac Gluten Sensitivity: A Multicentre StudyKamran Rostami, Arzu Ensari, Michael N Marsh, et al.
Pageof 3